Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Hyperactive KRAS/MAPK signaling disrupts normal lymphatic vessel architecture and function

Frontiers in Cell and Developmental Biology(2023)10.3389/fcell.2023.1276333Source: DataRank Database

Hyperactive KRAS/MAPK signaling disrupts normal lymphatic vessel architecture and function is a research paper published in Frontiers in Cell and Developmental Biology (2023). On theSindex it has a DataRank of 0. It has been cited 19 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access19 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: goldTopics (13)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Jeffrey D. Tresemer,Jing Zhang ORCID,Jonathan J. Rios ORCID,Joshua P. Scallan ORCID,Michael T. Dellinger ORCID

Live enrichment

PubMed:37842094 PMC:PMC10571159

NCI NIH HHS

Grant: R01 CA152108

NHLBI NIH HHS

Grant: R01 HL144793

National Institutes of Health

Grant: 5R01HL144793-04

Characterizing the Formation and Function of Bone Lymphatics

National Institutes of Health

Grant: 5R01CA152108-04

Molecular and Cellular Mechanisms of Chronic Myelomonocytic Leukemia (CMML)

Influential Citations

goldLicense: cc-by

GOLDhttps://www.frontiersin.org/articles/10.3389/fcell.2023.1276333/pdf?isPublishedV2=False

publisherhttps://www.frontiersin.org/articles/10.3389/fcell.2023.1276333/pdf?isPublishedV2=False

publisherhttps://www.frontiersin.org/articles/10.3389/fcell.2023.1276333/full

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10571159/pdf/fcell-11-1276333.pdf

repositoryhttps://doaj.org/article/ba2b069fed614929b94de62055977d42

Fields of Study

MedicineBiology0301 basic medicine03 medical and health sciences

Keywords

LymphangiogenesisKrasLymphatic MalformationTrametinibGorham-stout DiseaseComplex Lymphatic AnomalyCell and Developmental BiologyQH301-705.5Biology (General)

Additional file 1 of Targeted treatment in complex lymphatic anomaly: a case of synergistic efficacy of trametinib and sirolimus

10.6084/m9.figshare.26721396.v1figshare

Additional file 1 of Targeted treatment in complex lymphatic anomaly: a case of synergistic efficacy of trametinib and sirolimus

10.6084/m9.figshare.26721396figshare

Hyperactive KRAS/MAPK signaling disrupts normal lymphatic vessel architecture and function

FAIR Checklist

Authors (6)

Funding (4 grants)

Impact

Open Access

Topics

Linked Datasets (2)

Annotations (Europe PMC)